2.2 Controlled Substances Act (CSA) Schedules, Registration & Quotas

2.2 Controlled Substances Act (CSA) Schedules, Registration & Quotas

The regulation of controlled substances in the United States represents a closed, cradle-to-grave distribution system designed to prevent the diversion of abusable pharmaceuticals into illicit channels while guaranteeing an adequate, uninterrupted supply for legitimate medical, scientific, and industrial purposes. Enacted by Congress as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, the Controlled Substances Act (CSA) (codified at 21 U.S.C. § 801 et seq. and implemented via Title 21 of the Code of Federal Regulations, 21 CFR Parts 1300–1321) forms the federal framework governing every controlled drug handled by pharmacists.

---

1. Statutory Scheduling Authority & The Eight Factors

Under 21 U.S.C. § 811, the authority to classify, reschedule, or deschedule any drug or substance is vested in the Attorney General of the United States, who delegates this operational responsibility to the Administrator of the Drug Enforcement Administration (DEA). However, before initiating rulemaking, the DEA must request a scientific and medical evaluation and scheduling recommendation from the Secretary of Health and Human Services (HHS), conducted through the FDA.

The HHS Binding Recommendation

The Secretary's scientific and medical findings are binding on the DEA. If the Secretary recommends that a drug not be controlled, the DEA cannot schedule it. When evaluating a substance, the CSA mandates consideration of eight statutory factors (21 U.S.C. § 811(c)):

1. Its actual or relative potential for abuse;
2. Scientific evidence of its pharmacological effect, if known;
3. The state of current scientific knowledge regarding the drug or other substance;
4. Its history and current pattern of abuse;
5. The scope, duration, and significance of abuse;
6. What, if any, risk there is to the public health;
7. Its psychic or physiological dependence liability; and
8. Whether the substance is an immediate precursor of a substance already controlled.

Emergency / Temporary Scheduling Authority

Under 21 U.S.C. § 811(h), if the Attorney General finds that scheduling a substance on a temporary basis is necessary to avoid an imminent hazard to the public safety, the DEA may place that substance into Schedule I without waiting for the lengthy HHS scientific evaluation. Such temporary scheduling orders are effective for up to two years, with an optional one-year extension while formal rulemaking proceeds.

---

2. Exhaustive Analysis of the Five Controlled Substance Schedules

The CSA categorizes controlled substances into five schedules based upon three statutory criteria: accepted medical use in the United States, relative abuse potential, and the severity of physical or psychological dependence liability.

┌─────────────────────────────────────────────────────────────────────────────┐
│                     FEDERAL CSA SCHEDULING CRITERIA                         │
├──────────┬──────────────────┬───────────────────────┬───────────────────────┤
│ Schedule │ Abuse Potential  │ Accepted Medical Use  │ Dependence Liability  │
├──────────┼──────────────────┼───────────────────────┼───────────────────────┤
│ C-I      │ High             │ None in the U.S.      │ Severe (lack of safe  │
│          │                  │                       │ medical use)          │
├──────────┼──────────────────┼───────────────────────┼───────────────────────┤
│ C-II     │ High             │ Yes (or with severe   │ Severe physical or    │
│          │                  │ restrictions)         │ severe psychological  │
├──────────┼──────────────────┼───────────────────────┼───────────────────────┤
│ C-III    │ Less than C-I/II │ Yes                   │ Moderate / low phys;  │
│          │                  │                       │ high psychological    │
├──────────┼──────────────────┼───────────────────────┼───────────────────────┤
│ C-IV     │ Low rel. to C-III│ Yes                   │ Limited physical or   │
│          │                  │                       │ psychological         │
├──────────┼──────────────────┼───────────────────────┼───────────────────────┤
│ C-V      │ Low rel. to C-IV │ Yes                   │ Limited physical or   │
│          │                  │                       │ psychological         │
└──────────┴──────────────────┴───────────────────────┴───────────────────────┘

Schedule I (C-I)

• Statutory Profile: High potential for abuse; no currently accepted medical use in treatment in the United States; lack of accepted safety for use under medical supervision.
• Representative Substances:
  • Heroin, diacetylmorphine;
  • Hallucinogens: Lysergic acid diethylamide (LSD), mescaline, peyote, psilocybin, dimethyltryptamine (DMT);
  • Synthetic empathogens: 3,4-methylenedioxymethamphetamine (MDMA / Ecstasy);
  • Depressants: Methaqualone (Quaalude);
  • Illicit gamma-hydroxybutyric acid (GHB); Note: While illicit GHB is Schedule I, sodium oxybate oral solution under an approved NDA (Xyrem, Lumryz) is Schedule III under an FDA REMS program;
  • Cannabis: Marijuana and tetrahydrocannabinols (THC) remain federally classified in Schedule I under the CSA, notwithstanding state-level medical or recreational decriminalization laws;
  • Synthetic cannabinoids (e.g., "Spice", "K2") and synthetic cathinones (e.g., "bath salts").

Schedule II (C-II)

• Statutory Profile: High potential for abuse; currently accepted medical use in treatment in the U.S. (or accepted medical use with severe restrictions); abuse may lead to severe physical or severe psychological dependence.
• Representative Substances:
  • Opioids: Morphine, hydromorphone (Dilaudid), oxymorphone (Opana), oxycodone (alone or in combination: OxyContin, Percocet), hydrocodone (alone or in combination: Norco, Vicodin, Lortab — rescheduled from C-III to C-II nationwide on October 6, 2014), fentanyl (Duragesic, Actiq, Fentora), methadone (Dolophine), meperidine (Demerol), codeine (single-entity), tapentadol (Nucynta), levorphanol, sufentanil;
  • Stimulants: Amphetamine salts (Adderall), dextroamphetamine (Dexedrine), methamphetamine (Desoxyn), methylphenidate (Ritalin, Concerta), dexmethylphenidate (Focalin), lisdexamfetamine (Vyvanse), cocaine (topical local anesthetic);
  • Depressants: Amobarbital, pentobarbital, secobarbital (single-entity oral formulations);
  • Cannabinoids: Dronabinol oral solution (Syndros, 50% alcohol solution; classified as C-II due to rapid absorption and easy extraction profile, unlike Marinol capsules);
  • Hallucinogens/Precursors: Phencyclidine (PCP), nabilone (Cesamet).

Schedule III (C-III)

• Statutory Profile: Potential for abuse less than substances in Schedules I and II; currently accepted medical use in treatment; abuse may lead to moderate or low physical dependence or high psychological dependence.
• Representative Substances:
  • Buprenorphine (alone or with naloxone: Subutex, Suboxone, Zubsolv);
  • Dronabinol oral capsules (Marinol — synthetic delta-9-THC in sesame oil formulated in soft gelatin capsules);
  • Barbiturate combinations: Butalbital with aspirin (Fiorinal). Note: While federal law exempts Fioricet (butalbital/acetaminophen/caffeine) from federal scheduling due to its ratio, Tennessee state law strictly classifies Fioricet as a Schedule III controlled substance;
  • Amobarbital, pentobarbital, or secobarbital in suppository form or combined with non-controlled active ingredients;
  • Anabolic steroids: Testosterone (AndroGel, Depo-Testosterone), oxandrolone, nandrolone (under the Anabolic Steroids Control Act of 1990/2004);
  • Ketamine (Ketalar);
  • Paregoric (camphorated tincture of opium);
  • Sodium oxybate (Xyrem oral solution under approved NDA/REMS).
• Schedule III Narcotic Rule of Limits (21 CFR § 1308.13(e)):
  • Codeine Limit: Not more than 1.8 grams of codeine per 100 mL (18 mg/mL) or not more than 90 mg per dosage unit, combined with one or more active, non-narcotic ingredients in recognized therapeutic amounts (e.g., Tylenol with Codeine #3 [30 mg codeine / 300 mg APAP] and #4 [60 mg codeine / 300 mg APAP]);
  • Dihydrocodeine Limit: Not more than 1.8 g/100 mL or $\le 90\text{ mg}$ per dosage unit with active non-narcotic;
  • Ethylmorphine Limit: Not more than 300 mg/100 mL or $\le 15\text{ mg}$ per dosage unit with active non-narcotic;
  • Opium Limit: Not more than 500 mg/100 mL (or per 100 g) or $\le 25\text{ mg}$ per dosage unit with active non-narcotic;
  • Morphine Limit: Not more than 50 mg/100 mL (or per 100 g) with active non-narcotic.

Schedule IV (C-IV)

• Statutory Profile: Low potential for abuse relative to Schedule III; currently accepted medical use; abuse may lead to limited physical dependence or psychological dependence relative to Schedule III.
• Representative Substances:
  • Benzodiazepines: Alprazolam (Xanax), diazepam (Valium), lorazepam (Ativan), clonazepam (Klonopin), temazepam (Restoril), midazolam (Versed), triazolam (Halcion), chlordiazepoxide (Librium), oxazepam, flurazepam;
  • Sedative Hypnotics ("Z-drugs"): Zolpidem (Ambien), zaleplon (Sonata), eszopiclone (Lunesta);
  • Atypical Opioid Analgesics: Tramadol (Ultram, Ultracet — scheduled C-IV federally on August 18, 2014), butorphanol (Stadol);
  • Muscle Relaxants: Carisoprodol (Soma — scheduled C-IV on January 11, 2012);
  • Barbiturates: Phenobarbital;
  • Weight Management Stimulants: Phentermine (Adipex-P), diethylpropion;
  • Wakefulness Agents: Modafinil (Provigil), armodafinil (Nuvigil);
  • Orexin Receptor Antagonists: Suvorexant (Belsomra), lemborexant (Dayvigo).

Schedule V (C-V)

• Statutory Profile: Low potential for abuse relative to Schedule IV; currently accepted medical use; abuse may lead to limited physical dependence or psychological dependence relative to Schedule IV.
• Representative Substances:
  • Anticonvulsants / Neuropathic Agents: Pregabalin (Lyrica), lacosamide (Vimpat), brivaracetam (Briviact). Critical Tennessee Distraction: Gabapentin (Neurontin) is not scheduled federally under the CSA, but Tennessee state law classifies gabapentin as a Schedule V controlled substance;
  • Antidiarrheals: Diphenoxylate with atropine (Lomotil — not more than 2.5 mg diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit); difenoxin with atropine (Motofen — not more than 0.5 mg difenoxin and not less than 25 mcg atropine);
  • Antitussives (Rule of Limits; 21 CFR § 1308.15): Not more than 200 mg of codeine per 100 mL (or 100 g) combined with one or more non-narcotic active medicinal ingredients (e.g., Promethazine with Codeine [10 mg/5 mL = 200 mg/100 mL], Cheratussin AC [guaifenesin/codeine]);
  • Dihydrocodeine Limit: Not more than 100 mg/100 mL with active non-narcotic;
  • Ethylmorphine Limit: Not more than 100 mg/100 mL with active non-narcotic;
  • Opium Limit: Not more than 100 mg/100 mL with active non-narcotic.

---

3. Benchmark Drug Scheduling Summary Table

---

4. DEA Registration Architecture (21 CFR Part 1301)

The CSA mandates that every person or entity that manufactures, distributes, dispenses, imports, exports, or conducts research with controlled substances must obtain an independent registration from the DEA, unless explicitly exempted by law.

The Dispenser Registration: Pharmacy vs. Pharmacist

• The Practice Site Holds the Registration: In community and institutional pharmacy practice, the pharmacy itself registers with the DEA as a dispenser (retail pharmacy or hospital/clinic).
• Employed Pharmacists Do Not Register Separately: Individual staff pharmacists employed by a DEA-registered pharmacy do not obtain individual DEA registrations to dispense controlled substances. They practice under the legal authority of the pharmacy's institutional DEA registration.
• Individual Practitioners: Individual physicians (MD, DO), dentists (DDS, DMD), veterinarians (DVM), podiatrists (DPM), and licensed mid-level practitioners (nurse practitioners, physician assistants) must register individually with the DEA to prescribe, administer, or dispense controlled substances.

Core DEA Registration Forms

• DEA Form 224 (Initial Application): Used by retail pharmacies, hospital/clinics, practitioners, teaching institutions, and mid-level practitioners applying for initial registration.
• DEA Form 224a (Triennial Renewal): Used by retail pharmacies, hospitals, and practitioners to renew their registration every three (3) years. Renewal notices are sent electronically approximately 60 days before expiration; if not received by 45 days prior, the registrant must notify the DEA in writing.
• DEA Form 224b (Retail Chain Master Renewal): Enables corporate pharmacy chains operating 50 or more registered retail locations to submit a single consolidated renewal application.
• DEA Form 225 / 225a: Initial and renewal application for manufacturers, distributors, reverse distributors, researchers, analytical laboratories, importers, and exporters (renewed annually).
• DEA Form 363 / 363a: Initial and renewal registration for Narcotic Treatment Programs (Opioid Treatment Programs, OTPs; renewed annually).
• DEA Form 510 / 510a: Registration for wholesale distributors of List I chemicals (ephedrine, pseudoephedrine, phenylpropanolamine).

Certificate of Registration & Separate Physical Locations

• DEA Form 223: The official Certificate of Registration issued by the DEA. It must be maintained at the registered location and made readily available for official inspection by DEA investigators and state board inspectors.
• Separate Location Rule (21 CFR § 1301.12): A separate DEA registration is required for each principal place of business or professional practice where controlled substances are manufactured, distributed, or dispensed. A hospital operating an outpatient retail pharmacy on its campus must hold a separate DEA registration for the retail pharmacy if it dispenses to outpatients under a distinct practice site permit.
• Exceptions to Registration: Separate registration is not required for warehouse facilities used solely to store controlled substances on behalf of a registered site, or for an office used by a practitioner solely to solicit orders or prescribe where no controlled substances are administered, dispensed, or stored.

Modification, Termination & Transfer of Business (21 CFR § 1301.51–52)

• Modification of Registration: A registrant wishing to change its address, name, or registered business activities must submit an application online or in writing to the DEA. If approved, the DEA issues an amended Form 223. The registrant cannot move controlled substances to the new location until the modified registration is issued.
• Termination / Surrender of Registration: The DEA registration terminates if the registrant dies, ceases legal existence, discontinues business, or surrenders registration. The registrant must immediately notify the DEA, return the Certificate of Registration (Form 223), return any unused DEA Form 222 order forms, and dispose of controlled substances pursuant to DEA regulations.
• Transfer of Business (14-Day Notice Rule): A registrant transferring a pharmacy business to another registrant must notify the DEA Special Agent in Charge (SAC) in their area in person or by registered/certified mail at least 14 calendar days prior to the proposed transfer date. The notice must specify:
  1. Name, address, DEA number, and authorized schedule authority of the transferor and transferee;
  2. Whether business activities will continue at the current location or move;
  3. The exact date on which the transfer of controlled substances will occur.
• Transfer Day Protocol: On the transfer date, a complete controlled substance inventory must be taken by both parties. Schedule II substances must be transferred using DEA Form 222 (or CSOS) executed by the transferee (buyer). Schedule III–V substances are transferred via commercial invoice showing drug name, dosage form, strength, quantity, and date. All transfer records must be retained for 2 years.

---

5. Controlled Substance Quotas (21 U.S.C. § 826; 21 CFR Part 1303)

To prevent the overproduction of abusable substances that historically fueled pharmaceutical diversion, Congress established a statutory federal quota system administered exclusively by the DEA.

• Applicability: Quotas apply strictly to Schedule I and Schedule II controlled substances, as well as List I chemicals (ephedrine, pseudoephedrine, phenylpropanolamine). Quotas do not apply to Schedule III, IV, or V substances.
• Aggregate Production Quotas (APQ): Established annually by the DEA Administrator in consultation with HHS/FDA. The APQ represents the total quantity of each basic class of Schedule I and II substances necessary to satisfy the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the maintenance of reserve stocks.
• Individual Manufacturing Quotas: Allocated annually to registered bulk manufacturers. A manufacturer cannot exceed its individual manufacturing quota without submitting an application for an adjustment and receiving DEA approval.
• Procurement Quotas: Issued to dosage-form manufacturers who purchase bulk active pharmaceutical ingredients (APIs) to formulate finished tablets, capsules, liquids, or injectables.